SCYNEXIS, Inc. Payments of Loan Costs
SCYNEXIS, Inc. (SCYX) reported Payments of Loan Costs of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2024-03-28
- SCYNEXIS, Inc. payments of loan costs for the quarter ending 2023-12-31 was $0.00.
- SCYNEXIS, Inc. payments of loan costs for the quarter ending 2023-09-30 was $0.00.
- SCYNEXIS, Inc. payments of loan costs for the quarter ending 2022-12-31 was $0.00.
- SCYNEXIS, Inc. payments of loan costs for the quarter ending 2022-09-30 was $0.00.
- SCYNEXIS, Inc. payments of loan costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- SCYNEXIS, Inc. payments of loan costs for fiscal 2022 was $26.00K, a 97.92% decline from fiscal 2021.
- SCYNEXIS, Inc. payments of loan costs for fiscal 2021 was $1.25M.
- SCYNEXIS, Inc. payments of loan costs for fiscal 2020 was $0.00.
| Period end | Payments of Loan Costs 3 month | Payments of Loan Costs 6 month | Payments of Loan Costs 9 month | Payments of Loan Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $26.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $26.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $26.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $1.25M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.25M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $1.25M 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $0.00 10-K · filed 2022-03-29 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |